Lizenzierung von Technologien der Max-Planck-Gesellschaft
Investition in die Zukunft

Licensing agreements

On average, we close about 80 licensing agreements covering patented technologies with future-oriented companies. Among our industry partners are German and European companies as well as companies from the US, Japan, and other countries.

The nature and extent of the licenses are as varied as the payment modalities. They range from upfront payments and sales-based royalties to additional milestone payments (e. g. in the case of drug development) and annual minimum license fees. At present, several potential future blockbusters are in development at our industry partners’ sites. Moreover, many products, which are based on an MPGtechnology, such as medications, medicinal diagnostic devices, microscopes, biotechnological methods and processes, new materials, sensors, components and software are already on the market.

Licensees
  • Abbott
  • Abcam
  • AbD Serotec
  • Active Motif
  • AERAS
  • Aeterna Zentaris
  • Agrobiogen
  • Air Liquide Advanced Technologies
  • Akebia Therapeutics
  • Aldrich Chemical
  • Almax
  • Alvosys
  • Applied Biological Materials
  • Aprilage
  • Astellas Pharma
  • Asuragen
  • Athena Diagnostics
  • Atotech
  • Australian Synchrotron Company
  • Axxam
  • Baader Planetarium
  • BASF
  • Bayer
  • BD Biosciences
  • Big Sky Electronics
  • Biogemma
  • BioLegend
  • BIOTRONIK
  • Boehringer Ingelheim
  • Bruker Daltonik
  • Bruker BioSpin
  • Cairn Research
  • Carl Zeiss Jena
  • Covance Antibody Services
  • Createc Fischer
  • Dafra Pharma
  • Dako
  • Dolby
  • eBioscience
  • Eupheria Biotech
  • Excelitas
  • Exiqon
  • eyevis
  • FEI
  • Femtolasers
  • Ferro
  • Fovea Pharmaceuticals
  • FuMA-Tech
  • GATAN
  • Genemed Biotechnologies
  • Genzyme
  • GlaxoSmithKline
  • Helsinki University of Technology
  • Henkel
  • Heraeus Kulzer
  • HREM Research
  • IBA – Institut für Bioanalytik
  • ibidi
  • IMBA – Institute of Molecular Biotechnology
  • IPR – Institute for Plasma Research
  • Institute of Cancer Research
  • Invitrogen
  • IPT-Albrecht
  • IVA Analysentechnik
  • J. Schmalz
  • Japan Tobacco
  • JEOL
  • KeyGene
  • KUGLER
  • KUKA Roboter
  • KWS Saat
  • Leica
  • Life Technologies
  • Lundbeck
  • Medical & Biological Laboratories
  • Merck
  • MicroPlast
  • Millipore
  • Miltenyi Biotec
  • MIT – Massachusetts Institute of Technology
  • MoBiTec
  • New England Biolabs
  • Novartis
  • npi electronic
  • Paladin Labs
  • Pathway Genomics Corporation
  • Pfizer
  • PicoQuant
  • Pinteon Therapeutics
  • Pioneer
  • Plymouth University
  • QiagenQuest Diagnostics
  • Qurient
  • Radiometer Physics
  • Regulus Therapeutics
  • Roche
  • Rosetta Genomics
  • Sanofi-Aventis
  • Santa Cruz Biotechnology
  • Sartorius Stedim Biotech
  • Sekisui Virotech
  • Shionogi
  • Shuwen Biotechnologies
  • Siemens
  • Sigma-Aldrich
  • Sigmann Elektronik
  • Siluva
  • Soitec
  • Sonation
  • Source BioScience
  • Sutter Instrument
  • Swant
  • Synaptic Systems
  • TandemLaunch Technologies
  • TECAN
  • ThermoFisher Scientific
  • UCB Celltech
  • UltraFast Innovations
  • Unisense
  • University of Dundee
  • Vakzine Projekt-Management
  • Ventana Medical Systems
  • XiMo
  • ZYRUS
  • and many more

Max Planck Innovation (MI) offers excellent access to the extensive technology portfolio from the different Max Planck Institutes. With the foundation of the Lead Discovery Center (LDC), which bridges the gap between academia and pharma in early drug discovery, MI and LDC serve today’s needs of the pharmaceutical industry in a highly professional manner. The value of this has already been proven by the collaboration between the LDC and Bayer HealthCare, which resulted in a novel approach to cancer therapy, currently being tested in phase I clinical trials.

 

Professor Dr. Hanno Wild
Senior Vice President
Bayer Pharma AG
Global Drug Discovery
Candidate Generation & External Innovation

Our success strongly depends on the development of innovations, which are setting new standards. The collaboration with the Max Planck Institute for Biophysical Chemistry has produced cutting-edge products in the field of super resolution microscopy. Our STED- and GSDIM-microscopes, for example, are based on the research of Nobel Prize winner Stefan Hell and have revolutionized opportunities for life science research allowing novel discoveries to be made in the fields of virology, neuroscience and cancer.

 

Dr. Joachim Bradl
Leader Intellectual Property, Life Science, LL.M.
Leica Microsystems CMS GmbH

Ever since the start of Alnylam in 2002, Max Planck Innovation has been a strong partner with Alnylam to advance RNAi therapeutics to patients in need. Our close collaboration on intellectual property has been an invaluable part of the Alnylam story.

 

John Maraganore, Ph.D.
CEO
Alnylam Pharmaceuticals, Inc.

Downloads

Back to top